News and Announcements
Immuron & Monash University to Develop a Clostridium Difficile Therapeutic
- Published January 31, 2012 4:06PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Melbourne, Australia, 31 January 2012: Australian biopharmaceutical company Immuron Limited (ASX:IMC), manufacturer of Travelan, has entered into a collaboration Agreement with Monash University to develop a product or products that will be aimed at both Prevention and treatment of Clostridium difficile (C difficile) infections.
The therapeutic will be based on Immuron’s hyper-immune colostrums platform technology, with its proven safety.
—–
To view the full article, please click the link below.
Company Updates
Dogs First to Reduce Risk: QBiotics’ Smarter Path to Oncology Markets
QBiotics took a compound derived from a north Queensland rainforest tree all the way to veterinary registration before pursuing human oncology to de-risk its human cancer programme. Interim CEO Ebru Davidson argues that sequence – now backed by early responses across several human cancers – is the company’s real asset. The story that pulled Wholesale […]
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Backed By Leading Investment Groups and Family Offices
